About Longeveron Inc. - Class A Common stock (LGVN)
Longeveron Inc is a biotechnology company focused on developing cellular therapies to address age-related and life-threatening conditions. The company specializes in the research and commercialization of innovative treatments, particularly those utilizing mesenchymal stem cells derived from umbilical cord tissue. Longeveron aims to improve the quality of life for patients suffering from diseases such as Alzheimer’s and cardiac dysfunction by harnessing the potential of these advanced therapies to promote regeneration and improve overall health outcomes. Through its commitment to scientific research and clinical trials, Longeveron is at the forefront of modern medicine, exploring new avenues for healing and enhancing longevity. Read More
Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.
Longeveron Inc. (LGVN) reported Q2 2025 earnings with revenue missing estimates at $320K but a narrower EPS loss of $0.33. Stock fell 3.5% post-earnings amid clinical progress in HLHS and Alzheimer's trials.
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
MIAMI, May 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition.
MIAMI, May 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today reported financial results for the quarter ended March 31, 2025 and provided a business update.
